The platelet aggregation in children with epilepsy receiving valproic acid

• Published in: Thrombosis research Vol. 81; no. 4; pp. 471 - 476
• Main Authors: Tanindi, Sakir, Akin, Ridvan, Köseoǧlu, Vedat, Kürekçi, A.Emin, Gökçay, Erdal, Özcan, Okan
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Ltd 15-02-1996; Elsevier Science
• Subjects: Adolescent; Anticonvulsants - adverse effects; Anticonvulsants - therapeutic use; Biological and medical sciences; Blood Coagulation Tests; Child; Child, Preschool; children; Drug toxicity and drugs side effects treatment; Epilepsy - blood; Epilepsy - drug therapy; Female; Humans; impedance aggregometry; Male; Medical sciences; Pharmacology. Drug treatments; platelet aggregation; Platelet Aggregation - drug effects; Toxicity: blood; Valproic acid; Valproic Acid - adverse effects; Valproic Acid - therapeutic use; whole blood; whole blood; impedance aggregometry; Valproic acid; children; platelet aggregation; Human; Aggregation; Nervous system diseases; Platelet; Ex vivo; Hemostasis; Toxicity; Epilepsy; Central nervous system disease; Anticonvulsant; Child; Cerebral disorder
• ISSN: 0049-3848; 1879-2472
• DOI: 10.1016/0049-3848(96)00019-9

This study was performed to evaluate the aggregation changes in the whole blood samples of children with epilepsy receiving valproic acid. A total of 25 patients and 15 healthy volunteer adults were included in the study. Platelet aggregation study was performed in whole blood by impedance aggregometry. Platelet counts, the bleeding times, and clotting times of the patients were within normal limits. The aggregation time and maximum aggregation values revealed no significant difference except for those with 2 μg/ml collagen (p<0.01) between the two groups. Serum valproic acid levels of the children did not correlate with the maximum aggregation values induced by different concentrations of aggregating agents except for 20 μM ADP (r=−0.430, p<0.05). We concluded that the use of valproic acid does not result in thrombocytopenia and platelet dysfunction within therapeutic limits and the drug is reliable in the management of epilepsy.